相关实验视频

Updated: Jun 11, 2025

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

改变范式:新辅助疗法在早期乳腺癌中的转变性作用

Nader Hirmas¹, Johannes Holtschmidt¹, Sibylle Loibl^1,2

¹German Breast Group, 63263 Neu-Isenburg, Germany.

|September 28, 2024

概括

新辅助全身疗法 (NST) 在乳腺癌治疗中具有优势,使瘤衰退和反应评估成为可能. 优化NST疗法,包括向疗法和新药,可以改善高风险患者的治疗结果.

科学领域:

在瘤学瘤学.
医学研究医学研究
临床试验临床试验

背景情况:

新辅助全身疗法 (NST) 在乳腺癌管理中至关重要.
NST允许瘤下降阶段,并提供对治疗反应的见解.
病理完整反应 (pCR) 是评估NST疗效的关键终点.

研究的目的:

综合新辅助药临床试验的结果.
为优化高风险乳腺癌患者的治疗策略.
评估新药在NST中的作用.

主要方法:

对新辅助药临床试验数据的审查.
对治疗方案的分析,包括人环素,纳税素和向疗法.
对HER2阳性,三阴性和HR阳性/HER2阴性乳腺癌的结局评估.

主要成果:

标准的NST通常包括 antracyclines 和 taxanes.
双重抗HER2疗法适用于HER2阳性乳腺癌.
碳白金和免疫检查点抑制剂在TNBC和HR+/HER2-乳腺癌中表现有前途.

结论:

NST是乳腺癌治疗的重要组成部分,提供了显著的好处.
根据瘤亚型和风险分层来定制NST是必不可少的.
新兴疗法正在扩大优化新辅助乳腺癌治疗的选择.

关键词:

在HER2阳性患者中,HER2是阳性的.生物标志物生物标志物乳腺癌乳腺癌乳腺癌有效性有效性有效性.具有激素受体阳性的人.这是一种新辅助剂.病态的完整反应.在安全方面,安全是安全的.幸存率幸存率生存率三重阴性乳腺癌是什么

更多相关视频

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer

Published on: May 18, 2020

Generating a Murine Orthotopic Metastatic Breast Cancer Model and Performing Murine Radical Mastectomy

Generating a Murine Orthotopic Metastatic Breast Cancer Model and Performing Murine Radical Mastectomy

Published on: November 29, 2018

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...